Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience

Research output: Contribution to journalArticle

2 Scopus citations


Primary treatment of AL amyloidosis is to target the plasma cell clone which produces the immunoglobulin light chain precursor of amyloid fibrils. A number of chemotherapeutic regimens have been used and all have shown varying response in individual patients. Most recently, bortezomib (Velcade) has been used with consistent success as not only a primary but also a secondary line therapy for patients with either multiple-myeloma or AL amyloidosis. Here, we report the experience with use of bortezomib for AL amyloidosis at Indiana University Medical Center.

Original languageEnglish (US)
Number of pages1
Issue numberSUPPL. 1
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience'. Together they form a unique fingerprint.

  • Cite this